Powered by IST's

Vectura has an innovative and broad clinical pipeline that combines mid- and late-stage programmes with earlier-stage opportunities addressing large and fast-growing market sectors.

The respiratory pipeline comprises inhaled formulations of both branded and generic products for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).

In the neurological area, Vectura is exploiting its pulmonary delivery technology for indications such as Parkinsons disease and migraine, and is exploring additional opportunities for future development.

For other indications, Vectura has invested in the development of products for sexual dysfunction and diabetes. Whilst these are not areas of in-house development focus for Vectura, they present significant licensing opportunities.

BOO

SET TO GO

LONDON (Thomson Financial) - Vectura Group PLC said its chief executive officer CP Blackwell and chief financial officer AP Hyland lifted their stake in the company to 0.03 pct and 0.04 pct respectively after they bought its 50,000 shares each through an exercise of options at 61 pence per share.

The company also said its two non-executive directors JR Brown and AJM Richards increased their stake in the company to 0.02 pct and 0.04 pct respectively after they bought the same number of shares through an exercise of options at the same price.

Just bought an interest at 46.22p per share today. I successfully traded these before, having bought innovata shares before being taken over a year ago. I sold at 92p and have watch them fall on the general lack of interest in small phamas. This fall may have been exaggerated. Apparantly, Co. broker, Piper Jaffray estimates VEC will have net cash of around 75,000,000 or about 23p per share by end of March 2008 and values Co's 8 pulmonary and non-pulmonary marketed products at 56p per share. Presumably, therefore,its 8 late stage developments etc are not attributed a value by the market. Of course there are the development risks of failure but the Co. does spread its risks. It is interesting that Fidelity has recently increased its stake to 5% and other notified holders have been Aviva, Amvescap and Legal and General. Aggregate Directors holdings are 430,000 shares.

sp up firmly today at 47p having dropped below 38p recently.

moving up in a weak market sp 51.25p

Vectura Group Plc. announced positive data from an early proof of concept study of VR147, a product in development for the symptomatic treatment of migraine.

With the compelling data completed earlier, the company said it will assess licensing options both for VR147 and for the use of its inhalation technology for the delivery of other triptans.

VR147 is an orally inhaled triptan therapy with the potential to provide enhanced benefits to migraine patients through its rapid onset of action, the pulmonary product development company said.

The triptan market currently dominates migraine therapy, with sales in excess of $2.3 billion in 2007

Vectra continues its recovery and is up over 20% over the past week. It is working with a Novartis subsidiary on a version of blockbuster asthma drugs. It is hoped that a cut price alternative to GSK's Advair and AstraZ's Symbicort can be produced once their Patents have run out.(brief summary of IC buy recomendation). I think Advair expires around 2013.

At a presentation given at Deutsche Bank 33rd Annual Health Care Conference Co said that it had a mature product pipeline and a stage development points. Has a steady revenue stream and strong cash position and will be cash generative this year although this is not necessarily consistant depending on its developments.

As Baylis mentions re VR147 they state that triptan is a big niche opportunity and phase 1 study early proof of concept product is safe and works, in that earlier relief is given when drug is inhaled. sp 60.5p

http://webcastingplayer.corporate-ir.net/player/PlayerHost.aspx?Ev

Should also of mentioned that they have continuing success with the Girohaler which the Co licenses out and are developing a variant of Girohaler for German Company Boehringer Ingelheim for use with their products.

Finals due to be announced on 22nd May.

understandable profit taking sp 56p but believe the sp is in upward trend. Holding for now.

Vectura Group said full year sales were up 80% to 25.2m, while pretax losses widened to 21.4m compared with a restated 8.5m last time.

The inhaled drug specialist said cash at its year-end point was 78.8m compared with 77.5m last year, and added that it has spent 29.7m in R&D, a 75% year-on-year increase.

The company said it is exploring partnering one or more of its proprietary programmes, including its migraine therapy, VR147, and its sexual dysfunction programme, which includes its inhaled drugs for erectile dysfunction, VR004, and premature ejaculation, VR776.

It said it was confident that it will achieve its goal of reaching a sustainable cash-generative position, aided by substantial milestones and royalties from its partners as its late-stage respiratory programmes are filed and come to market.

The company in a statement that its good performance was down to its acquisition of Innovata, a lung product specialist, in January 2007, for 131m in an all-share deal.

'This strong financial performance is attributable to the addition of the Innovata business, which contributed over 17m, or 68%, of revenues and 8.6m of earnings before interest, taxes, depreciation and amortisation (EBITDA).

'Our goal, to become a sustainable, self-funding principal player in the development of inhaled pharmaceutical products, has been strengthened by the acquisition and is validated by these results,' it said.

The acquisition of Innovata gave it established alliances with a number of additional companies, such as Baxter International, GlaxoSmithKline, Merck Generics (part of Mylan Inc), UCB and Otsuka Corp, the company said.

Company looking to be making headway. However, sold at 56p to book a good profit. If sp weakens again through lack of interest given general market conditions, I will consider repurchase.

LOOKS GOOD

Any idea what's going on here?

A good IMS, but the price is dropping rapidly

Red

Red - I was wondering about that too and the only thing I can find is that The Naked Trader announced on Friday he'd sold his shares in Vectura.

As I commented on the Naked Trader thread, his buys and sells move the market quite dramatically nowadays.

Well that was certainly some dip, but I would have thought such a dramatic change would have prompted some comment from the company even if it was " we no of no reason ..."

Is the dip over & done I wonder!

Not a profitable company at present, but quite highly rated by some analysts.

http://uk.finance.yahoo.com/q/ao?s=VEC.L

Even 87p would look good!


Red

VR496 (cystic fibrosis) * Phase II proof-of-concept study results on track to read out in March 2011

Final year results out today and looking good for the future. Broker target of 120.

Peel Hunt reiterates buy with 132 target.